Treatment of Wegener's Granulomatosis With Cyclophosphamide
Status:
Completed
Trial end date:
2002-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis
who have already entered the study, and to treat new patients. The investigators will attempt
to correlate the clinical response with specific immunosuppressive effects of drug
administration. The investigators are accumulating data on the optimal duration and side
effects of therapy.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)